Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease

Takeda Pharmaceutical Company Limited (OTC: TKPYY ) and Natrogen Therapeutics International, Inc. (“Natrogen”) jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's